KOSPIBiotech & Pharma128940

Hanmi Pharm

₩441,000▼ 1.67%2026-11-18 close
Market Cap
₩5.6T
Turnover
₩30.4B
Volume
70K
Shares out.
12.8M
PER
31.2×
PBR
4.3×
EPS
₩14,908
Dividend Yield
0.43%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩2,000 per share · Prices as of the 2026-11-18 close

01

Report overview

Licensing deals grow, but quarterly profit still swings

Hanmi Pharm signed three global licensing deals in 2026, yet its reported operating profit still moves sharply from quarter to quarter depending on when upfront payments are recognized.

  1. 1

    Revenue reached KRW 1.55 trillion in 2025 and has risen for three straight years since 2023, while operating profit of KRW 257.8 billion was the largest of 2022 to 2025.

  2. 2

    The confirmed upfront payments from the three 2026 licensing deals with Eli Lilly, Genentech and BioMarin total about USD 335 million.

  3. 3

    Operating profit in the third quarter of 2026 was KRW 37.8 billion, down 31.3% from a year earlier, which the company attributed to the base effect of an upfront payment recognized in the prior quarter.

  4. 4

    Rosuzet, the core prescription product, posted third-quarter 2026 prescription sales of KRW 65.2 billion, up 10.6% year on year.

  5. 5

    Revenue declines at the Chinese subsidiary Beijing Hanmi Pharmaceutical and a dispute among major shareholders over control are the main uncertainties.

02

Business structure

Hanmi Pharm is a pharmaceutical company built on two pillars: prescription drug sales in Korea and in-house R&D that feeds global licensing deals.

The core of its domestic prescription business is Rosuzet, a combination drug for dyslipidemia, whose third-quarter 2026 prescription sales were KRW 65.2 billion, up 10.6% year on year.

The Amosartan family for hypertension and the Esomezol family for acid reflux disorders recorded prescription sales of KRW 38.2 billion and KRW 15.2 billion in the same quarter.

Cumulative third-quarter 2026 prescription sales stood at KRW 783.5 billion on the UBIST basis, and the company expects to keep its rank as the largest domestic prescription seller for a ninth consecutive year.

Its Chinese subsidiary Beijing Hanmi Pharmaceutical handles overseas sales, and its third-quarter 2026 revenue of KRW 79.3 billion fell 15.8% year on year.

The API subsidiary posted third-quarter 2026 revenue of KRW 22.8 billion, up 32.6%, and returned to profit on rising contract manufacturing orders in a competitive cephalosporin raw-material market.

R&D spending rose each year, reaching KRW 229.0 billion in 2025, and the company has typically devoted 14% to 15% of revenue to R&D. Third-quarter 2026 R&D spending of KRW 62.3 billion equaled 16.5% of revenue.

The obesity drug market has been expanded mainly by imported products such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, and Hanmi Pharm positions its Pyeongtaek bio plant as a base for supply reliability and price competitiveness.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩362.3B₩55.1B15.2%
2025Q4₩433B₩83.3B19.2%
2026Q1₩392.9B₩53.6B13.7%
2026Q2₩467.2B₩131.1B28.1%
2026Q3₩377.4B₩37.8B10.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.3T₩158.1B₩82.8B11.9%9.5%90.7%
2023₩1.5T₩220.7B₩146.2B14.8%15.3%72.6%
2024₩1.5T₩216.2B₩121.3B14.5%11.2%62.9%
2025₩1.5T₩257.8B₩169.6B16.7%13.6%50.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual results show revenue and operating profit rising together. Revenue went from KRW 1.33 trillion in 2022 to KRW 1.49 trillion in 2023 (up 12.0%), KRW 1.5 trillion in 2024 (up 0.3%) and KRW 1.55 trillion in 2025 (up 3.5%), and has risen for three consecutive years from 2023 through 2025.

Operating profit rose from KRW 158.1 billion in 2022 to KRW 220.7 billion in 2023 (up 39.6%), dipped to KRW 216.2 billion in 2024 (down 2.0%), and reached KRW 257.8 billion in 2025 (up 19.2%), the largest year of 2022 to 2025. The operating margin was 11.9% in 2022, 14.8% in 2023, 14.5% in 2024 and 16.7% in 2025.

Profit attributable to owners of the parent was KRW 82.8 billion in 2022, KRW 146.2 billion in 2023 (up 76.6%), KRW 121.3 billion in 2024 (down 17.0%) and KRW 169.6 billion in 2025 (up 39.8%).

Net profit including non-controlling interests, at KRW 187.1 billion in 2025, is a separate figure from profit attributable to owners of the parent. The debt-to-equity ratio fell from 90.7% in 2022 to 50.2% in 2025, with total equity of KRW 1.42 trillion and total liabilities of KRW 714.7 billion at the end of 2025.

Operating cash flow peaked at KRW 216.5 billion in 2023 and was KRW 173.1 billion in 2025. Quarterly results are far less even.

Operating profit was KRW 83.3 billion in the fourth quarter of 2025, KRW 53.6 billion in the first quarter of 2026 (down 35.6% from the prior quarter) and KRW 131.1 billion in the second quarter (up 144.4%).

The second-quarter figure included the one-time recognition of an upfront payment from the sonefpeglutide licensing deal, and the reversal of that base effect weighed on third-quarter operating profit of KRW 37.8 billion, down 31.3% year on year.

Profit attributable to owners of the parent was KRW 12.2 billion in the third quarter, down 69.5% from a year earlier. Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, that profit totaled KRW 189.2 billion, above the full-year 2025 figure of KRW 169.6 billion.

05

Industry analysis

Licensing deals by Korean pharmaceutical and biotech companies were worth about USD 15 billion in 2025, and publicly disclosed contract totals exceeded USD 11 billion by August 2026, according to Yonhap News. Hanmi Pharm's 2026 deals are among the main examples of this trend.

The sonefpeglutide deal with Eli Lilly in June carries a confirmed upfront payment of USD 75 million (about KRW 112.9 billion) and a total value of up to USD 1.26 billion including stage-based milestones.

The obesity candidate HM17321 licensed to Genentech in August has a total value of up to USD 2.3 billion and an upfront payment of USD 190 million.

The LA-GLA Fabry disease candidate licensed to BioMarin at the end of October has a total value of up to USD 475 million, and its co-developer GC Biopharma shares an upfront payment of USD 70 million.

Press tallies of the three deals' combined value differ: MT Business put the total at KRW 5.4039 trillion, while Herald Business reported a cumulative USD 4.035 billion (about KRW 5.72 trillion).

Coverage also notes that licensing activity is spreading from venture biotech firms to established pharmaceutical companies, with Yuhan and others pursuing follow-on commercialization.

A large share of the deal value depends on milestones, so the announced contract size and the timing of revenue recognition are separated by time.

06

Outlook

The outlook rests on three threads. First, sonefpeglutide, a GLP-2 analog for short bowel syndrome, is in a global Phase 2 trial in the United States, Europe and Korea, with a once-monthly subcutaneous formulation as the development target.

According to the company, it holds orphan drug designations from the FDA, EMA and Korea's MFDS, along with FDA Fast Track and pediatric rare disease designations. Second, HM17321, an obesity and diabetes candidate aimed at weight loss with muscle preservation, is in Phase 1 testing.

Third, Shinhan Investment said expectations for out-licensing of remaining obesity candidates HM15275 and HM-500197 would persist.

In a note dated November 3, 2026, Daol Investment & Securities raised its 2026 operating profit estimate from KRW 349.2 billion to KRW 391.1 billion to reflect the BioMarin upfront payment expected in the fourth quarter, and it raised its target price from KRW 700,000 to KRW 710,000.

These are broker estimates, not reported results. Much of the deal value depends on milestones, so revenue recognition will take time. The Pyeongtaek bio plant also supplies the active ingredient for products sold in the United States.

The next checkpoints are how much of the BioMarin upfront payment is recognized in the fourth quarter and when the Phase 2 sonefpeglutide data will be released.

07

Valuation

PER
31.2×
PBR
4.3×
ROE
14.8%
EPS
₩14,908
BPS
₩107,898
Dividend per share
₩2,000

Valuation reads most clearly when viewed through three relationships: book value, earnings level and the source of those earnings. The price-to-book ratio sits well above 1x, which means the stock carries a large premium over book value.

Against shareholders' equity attributable to owners of the parent of KRW 1.25 trillion and total equity of KRW 1.42 trillion at the end of 2025, the share price is set well above net asset value.

On earnings, profit attributable to owners of the parent over the last four quarters totaled KRW 189.2 billion, above the full-year 2025 figure of KRW 169.6 billion.

However, upfront licensing payments lifted second-quarter operating profit to KRW 131.1 billion and third-quarter operating profit fell to KRW 37.8 billion. Multiples therefore depend on which period's earnings are used, so the timing of upfront recognition is the key variable in reading them.

R&D spending at roughly 14% to 15% of revenue is also a fact to weigh when relating earnings to the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Three licensing agreements signed

In 2026 Hanmi Pharm signed licensing deals with Eli Lilly for sonefpeglutide in June, with Genentech for HM17321 in August and with BioMarin for LA-GLA at the end of October. Herald Business put the confirmed upfront payments across the three deals at USD 335 million, about KRW 469.3 billion.

Total deal values include stage-based milestones and royalties, leaving room for further revenue as clinical and regulatory steps advance.

Prescription franchise

Rosuzet's third-quarter 2026 prescription sales rose 10.6% year on year to KRW 65.2 billion, and cumulative third-quarter prescription sales reached KRW 783.5 billion. The company believes it is likely to remain the top domestic prescription seller for a ninth consecutive year.

Coverage points to the reinvestment of prescription drug profits into R&D as the foundation behind its licensing record.

CDMO and production base

The API subsidiary's third-quarter 2026 revenue rose 32.6% year on year to KRW 22.8 billion, and it moved to profit at both the operating and net levels. The Pyeongtaek bio plant is cited as supply infrastructure for injectable obesity drugs, supporting price competitiveness. Sonefpeglutide is in a global Phase 2 trial aimed at a once-monthly injection.

09

Bear factors

Quarterly profit volatility

Second-quarter 2026 operating profit of KRW 131.1 billion was driven largely by the one-time recognition of an upfront payment, while third-quarter operating profit of KRW 37.8 billion fell 31.3% year on year.

The bear case points out that profit clusters in quarters with deal recognition, leaving quarters without deals thin.

Weak Chinese subsidiary

Beijing Hanmi Pharmaceutical's third-quarter 2026 revenue of KRW 79.3 billion fell 15.8% year on year, and its operating profit of KRW 5.9 billion fell 75.1%. The company is adjusting bidding strategy and supply volumes to respond to China's volume-based procurement system. New transactions with a distribution channel have been halted until receivables are collected.

Clinical-stage pipeline

Sonefpeglutide is a Phase 2 candidate, and its commercial outcome will depend on development results still to come. HM17321 is in Phase 1 testing. Much of the headline deal value depends on milestones, so it cannot be treated as cash in hand.

10

Risk factors

Governance

Reports point to continuing control disputes among major shareholders, which keep governance uncertain. An industry source said governance issues could amplify short-term volatility. How the dispute affects R&D timelines and licensing negotiations is the next point to track.

China distribution and receivables

Beijing Hanmi Pharmaceutical saw both revenue and operating profit fall in the third quarter of 2026, and new transactions remain suspended until receivables are collected. The company says it is strengthening internal controls.

Continued price and volume pressure from procurement rules could slow the recovery, making the Chinese subsidiary's sales trend next quarter a key point to monitor.

Clinical outcomes and competition

Demand for obesity treatments is growing around imported products such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro. Hanmi Pharm's candidates are in Phase 1 and Phase 2 trials, so development results are not yet settled. Even large upfront payments could shrink milestone receipts if development is halted or terms change.

11

What to watch next

  1. Around February 2027 (typical schedule)

    Check how much of the BioMarin upfront payment is recognized in fourth-quarter 2026 results. Read together with Beijing Hanmi Pharmaceutical's sales trend, this shows the likely size of quarterly swings in operating profit.

  2. Around late March 2027 (annual report filing deadline)

    The 2026 annual report will fix full-year revenue, operating profit, profit attributable to owners of the parent, the debt-to-equity ratio and operating cash flow as reported figures. The change from the 2025 operating cash flow of KRW 173.1 billion is the point to check.

  3. 2027 or later (date not yet set)

    Results from the global Phase 2 trial of sonefpeglutide are the key event that will shape commercialization prospects. Progress of the HM17321 Phase 1 study is a second point to track.

12

Overall view

Hanmi Pharm's 2026 has been a year in which licensing deals and core business results moved at different speeds. The company signed three global licensing deals, with confirmed upfront payments totaling about USD 335 million.

Its core prescription business continues to grow led by Rosuzet, and cumulative third-quarter 2026 prescription sales reached KRW 783.5 billion. On reported figures, 2025 operating profit of KRW 257.8 billion was the largest of 2022 to 2025, with an operating margin of 16.7%.

By contrast, third-quarter 2026 operating profit of KRW 37.8 billion fell 31.3% year on year, and quarterly profit moved sharply with the timing of upfront recognition. The revenue decline at the Chinese subsidiary and the control dispute among major shareholders remain variables to watch.

The bullish case rests on pipeline value and upfront inflows, while the bearish case rests on profit volatility and clinical-stage uncertainty. The next checkpoints are fourth-quarter 2026 results and the 2026 annual report. This report is provided for information only and contains no buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. pharmnews.com
  2. ftoday.co.kr
  3. vegannews.co.kr
  4. betanews.net
  5. news.bizwatch.co.kr
  6. webeconomy.co.kr
  7. businesskorea.co.kr
  8. kpanews.co.kr
  9. thebionews.net
  10. supple.kr
  11. speconomy.com
  12. m.news.nate.com
  13. hankyung.com
  14. supple.kr
  15. supple.kr
  16. news.nate.com
  17. mt.co.kr
  18. etoday.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis